Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Local and regional treatment response by 18FDG-PET-CT-scans 4 weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC.
van Diessen JNA, La Fontaine M, van den Heuvel MM, van Werkhoven E, Walraven I, Vogel WV, Belderbos JSA, Sonke JJ. van Diessen JNA, et al. Among authors: van werkhoven e, van den heuvel mm. Radiother Oncol. 2020 Feb;143:30-36. doi: 10.1016/j.radonc.2019.10.008. Epub 2019 Nov 22. Radiother Oncol. 2020. PMID: 31767474 Clinical Trial.
Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
Uyterlinde W, Belderbos J, Baas C, van Werkhoven E, Knegjens J, Baas P, Smit A, Rikers C, van den Heuvel M. Uyterlinde W, et al. Among authors: van werkhoven e, van den heuvel m. Clin Lung Cancer. 2013 Sep;14(5):541-8. doi: 10.1016/j.cllc.2013.04.001. Epub 2013 Jul 5. Clin Lung Cancer. 2013. PMID: 23835165
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.
Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF, Roth JA. Chang JY, et al. Among authors: van den borne be, van werkhoven e. Lancet Oncol. 2015 Jun;16(6):630-7. doi: 10.1016/S1470-2045(15)70168-3. Epub 2015 May 13. Lancet Oncol. 2015. PMID: 25981812 Free PMC article. Clinical Trial.
Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial.
Louie AV, van Werkhoven E, Chen H, Smit EF, Paul MA, Widder J, Groen HJ, van den Borne BE, De Jaeger K, Slotman BJ, Senan S. Louie AV, et al. Among authors: van den borne be, van werkhoven e. Radiother Oncol. 2015 Oct;117(1):44-8. doi: 10.1016/j.radonc.2015.08.011. Radiother Oncol. 2015. PMID: 26492839 Clinical Trial.
Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
Reesink DJ, Fransen van de Putte EE, Vegt E, De Jong J, van Werkhoven E, Mertens LS, Bex A, van der Poel HG, van Rhijn BW, Horenblas S, Meijer RP. Reesink DJ, et al. Among authors: van rhijn bw, van werkhoven e, van der poel hg. J Urol. 2016 Apr;195(4 Pt 1):907-12. doi: 10.1016/j.juro.2015.11.025. Epub 2015 Nov 17. J Urol. 2016. PMID: 26598424
Factors associated with patient-reported cosmetic outcome in the Young Boost Breast Trial.
Brouwers PJ, van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, van Loon J, Maduro JH, Russell NS, Scheijmans LJ, Schinagl DA, Westenberg AH, Poortmans P, Boersma LJ; Young Boost Trial research group. Brouwers PJ, et al. Among authors: van loon j, van werkhoven e. Radiother Oncol. 2016 Jul;120(1):107-13. doi: 10.1016/j.radonc.2016.04.017. Epub 2016 May 28. Radiother Oncol. 2016. PMID: 27247055 Clinical Trial.
135 results